search
Back to results

Safety and Efficacy of RPH-104 Used to Prevent Recurrent Fever Attacks in Adult Patients With Colchicine Resistant or Colchicine Intolerant Familial Mediterranean Fever

Primary Purpose

Familial Mediterranean Fever, FMF

Status
Recruiting
Phase
Phase 2
Locations
International
Study Type
Interventional
Intervention
RPH-104
Sponsored by
R-Pharm International, LLC
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Familial Mediterranean Fever focused on measuring RPH-104, colchicine inefficacy, colchicine intolerance, colchicine resistance, subcutaneous

Eligibility Criteria

18 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. The patient who completed the last visit of the treatment period in the core study, according to the protocol, during which he/she received at least one dose of RPH-104.
  2. Voluntarily signed and dated Patient Informed Consent Form for participation in this study.
  3. The patient's ability and desire, according to the investigator, to follow the schedule of visits, follow the study procedures and follow the protocol requirements, i.e they agree to:

    • come to the study site every 2 weeks for the investigational product administration by qualified site staff. OR
    • learn the subcutaneous injection technique and self-administer the investigational product at home as per protocol of this study.

Exclusion Criteria:

  1. Any medically important event that was observed in a patient during his/her participation in the core study, and, in the opinion of the investigator, is a reason for not including this patient in the present study, and any other medical (including psychiatric) conditions or laboratory abnormalities, which may increase the potential risk associated with participation in the study and receiving the investigational product, or may affect the interpretation of the results of the study, and which, in the Investigator's reasonable opinion, result in the patient's non-compliance with the inclusion criteria
  2. Pregnant and/or lactating women or women planning pregnancy during the study or within 2 months after the last dose of the study drug.
  3. Women of childbearing potential, i.e. all women with the physiological ability to become pregnant (except for women with a final cessation of menstruation, which should be determined retrospectively after 12 months of natural amenorrhea, i.e. amenorrhea with an appropriate clinical status, for example, an appropriate age), who DO NOT agree to use highly effective contraception for of the entire study period, starting from the beginning of the screening phase (signing informed consent) and for a minimum of 8 weeks after the last dose of the study drug. OR

    Men who are sexually active and do NOT agree to use highly effective contraceptives throughout the study, starting from the beginning of the screening phase and for at least 8 weeks after the last dose of the study drug.

    Highly effective contraception methods include:

    • sterilization in women: surgical bilateral removal of the ovaries (with or without removal of the uterus) or ligation of the fallopian tubes at least 6 weeks before the start of the study therapy. In the case of removal of only the ovaries, the reproductive status of a woman should be confirmed by a subsequent assessment of hormone level;
    • sterilization in men, at least 6 months before the start of the study therapy with proper documentation of the absence of sperm in the ejaculate after vasectomy. For the women participating in the study, the sexual partner after a vasectomy should be the only partner;
    • using a combination of any two of the following methods (a+b or a+c or b+c):

      1. the use of oral, injectable or implanted hormonal contraceptives; in the case of the use of oral contraceptives, women should constantly use the same drug for at least 3 months before the start of the study therapy;
      2. the installation of an intrauterine device or contraceptive system;
      3. barrier methods of contraception: condom or occlusive cap (diaphragm or cervical cap/contraceptive vaginal ring) with spermicidal foam/gel/film/cream/vaginal suppository.
  4. The need for systemic glucocorticoid therapy at doses > 0.2 mg/kg/day of prednisolone (0.16 mg/kg/day of methylprednisolone or an equivalent dose of another glucocorticoid) orally from the moment of signing the Informed Consent Form to the end of the period of therapy with the study drug.
  5. The need to use a live (attenuated) vaccine during the study or within 3 months after the last dose of the study drug. Live attenuated vaccines include vaccines against viruses: measles, rubella, mumps, chickenpox, rotavirus, flu (as a nasal spray), yellow fever, polio (oral polio vaccine); vaccines against tuberculosis (BCG), typhoid fever (oral typhoid vaccine) and typhus (typhus vaccine). Immunocompetent family members of the patient should not be vaccinated with the oral polio vaccine during the patient's participation in the study.
  6. Positive results of tuberculosis screening performed at Visit 10 of the core study (QuantiFERON-TB/T-SPOT.TB test, chest x-ray).

Sites / Locations

  • Center of Medical Genetics and Primary Health Care LLCRecruiting
  • Mikaelyan Institute of Surgery CJSCRecruiting
  • LLC Tbilisi State Medical University and Ingorokva High Medical Technology University ClinicRecruiting
  • Inova LLCRecruiting
  • Medical Technologies Ltd.Recruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

RPH-104 80 mg q2w (160 mg q2w) depending on the dose in the core CL04018065 study

Arm Description

RPH-104 80 mg once every 2 weeks subcutaneously or RPH-104 160 mg once every 2 weeks subcutaneously (In case of FMF attack development, patients who receive 80 mg of the drug may be switched to the increased maximum drug dose 160 mg based at the discretion of the investigator. A dose of 160 mg should be administered by two subcutaneous injections in two different quadrants.)

Outcomes

Primary Outcome Measures

Incidence of Treatment-Emergent Adverse Events (AEs), by System Organ Class and Preferred Term
Incidence of Treatment-Emergent Serious Adverse Events (SAEs), by System Organ Class and Preferred Term
Incidence of Treatment-Emergent Adverse Events of Special Interest (AESI), by System Organ Class and Preferred Term
Incidence rate for serious adverse events (SAEs)
Incidence rate, expressed as the number of events per 100 patient-years of follow-up, for SAEs
Incidence rate for adverse events of special Interest (AESI)
Incidence rate, expressed as the number of events per 100 patient-years of follow-up, for AESI

Secondary Outcome Measures

Physician global assessment of disease activity scale (PGA)
Percentage of patients with physician global assessment of disease activity scale (PGA) <2. PGA of disease activity involves a 5-point system: from 0 = no clinical signs and symptoms associated with the disease to 4 = severe clinical signs and symptoms associated with the disease.
Percentage of patients with serological remission
Percentage of patients with serological remission (i.e., C-reactive protein (CRP) level ≤10 mg/L).
Percentage of patients whose Serum amyloid A (SAA) levels returned to normal values
Percentage of patients whose SAA levels returned to normal values (i.e. SAA <10 mg/L)
Percentage of patients who have experienced ≥ 1 attacks per month (since Day 0)
Percentage of patients who have experienced ≥ 1 attacks per month (since Day 0). Criteria for the diagnosis of an attack are defined as the simultaneous development of clinical and serological signs of an attack, including: the score on the scale of global physician's assessment of disease activity (PGA) ≥ 2, suggesting "mild", "moderate" or "severe" activity of the disease (i.e., clinical signs), AND CRP level ≥ 30 mg/L (i.e. serological signs)
Percentage of patients who have not had a single attack
Percentage of patients who have not had a single attack. Criteria for the diagnosis of an attack are defined as the simultaneous development of clinical and serological signs of an attack, including: the score on the scale of global physician's assessment of disease activity (PGA) ≥ 2, suggesting "mild", "moderate" or "severe" activity of the disease (i.e., clinical signs), AND CRP level ≥ 30 mg/L (i.e. serological signs)
Increase in the dose of the study drug
Percentage of patients who required an increase in the dose of the study drug to 160 mg twice weekly.
Additional symptomatic FMF therapy
Percentage of patients who have received additional symptomatic FMF therapy with NSAIDs, paracetamol or glucocorticoids.
Changes in the inflammatory markers over time
Changes in the inflammatory markers over time - CRP
Changes in the inflammatory markers over time
Changes in the inflammatory markers over time - SAA.
Changes in the PGA score over time
Changes in the PGA score over time. PGA of disease activity involves a 5-point system: from 0 = no clinical signs and symptoms associated with the disease to 4 = severe clinical signs and symptoms associated with the disease.
Changes in the severity of the main disease symptoms score
Changes in the severity of the main disease symptoms score. An assessment of severity of the main symptoms of the disease will also be based on a 5-point scale for the following symptoms: chest pain, abdominal pain, arthralgia/arthritis, skin rash. The severity of each symptom should be evaluated as follows: 0 = no symptom, 1 = minimal, 2 = mild, 3 = moderate, 4 = severe.
Changes in the renal function in patients with impaired renal function at the screening
Changes in the renal function in patients with impaired renal function (ClCr <90 ml/min [calculated using the Cockcroft-Gault formula] at the screening)
Changes in urinary protein levels in patients with proteinuria at the screening
Median changes from baseline (timepoint week 0) to timepoint week 62.

Full Information

First Posted
November 3, 2021
Last Updated
February 9, 2023
Sponsor
R-Pharm International, LLC
Collaborators
Atlant Clinical LLC, Center for Pharmaceutical Analytics LLC, Unimed Laboratories CJSC, Data Management 365
search

1. Study Identification

Unique Protocol Identification Number
NCT05190991
Brief Title
Safety and Efficacy of RPH-104 Used to Prevent Recurrent Fever Attacks in Adult Patients With Colchicine Resistant or Colchicine Intolerant Familial Mediterranean Fever
Official Title
An International Multicenter Open-label Clinical Study of the Safety and Efficacy of RPH-104 for Prevention of Recurring Attacks in Adult Subjects With Familial Mediterranean Fever With Resistance to or Intolerance of Colchicine
Study Type
Interventional

2. Study Status

Record Verification Date
February 2023
Overall Recruitment Status
Recruiting
Study Start Date
October 5, 2021 (Actual)
Primary Completion Date
August 2026 (Anticipated)
Study Completion Date
August 2026 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
R-Pharm International, LLC
Collaborators
Atlant Clinical LLC, Center for Pharmaceutical Analytics LLC, Unimed Laboratories CJSC, Data Management 365

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The primary purpose of this study is to assess the safety of the long-term treatment with RPH-104 at doses 80 mg or 160 mg once every 2 weeks in a population of patients with colchicine resistant or colchicine intolerant familial Mediterranean fever (FMF) who completed the core study, during which they received at least one dose of RPH-104. Long-term efficacy of RPH-104, the immunogenicity of the RPH-104, the pharmacokinetics of the RPH-104 and quality of life change in the population of patients receiving long-term treatment with RPH-104 will be assessed as well.
Detailed Description
This long-term open-label study is an extension of the core double blind, randomized, placebo-controlled study, CL04018065. It is planned that this study will include no more than 60 patients who completed the core study, where they received blinded therapy. This study will have the following periods: Screening period - within one day, Day 0, which is also the day of Visit 11 of the main study. This period envisages unblinding of the treatment groups determined in the main study (for not-unblinded patients) and determination of the eligibility for this study. Patients who do not meet the inclusion/exclusion criteria will not receive treatment with the study drug, such patients should attend a safety follow-up visit 6 weeks after the screening period (i.e. 8 weeks after the last injection of the study drug or placebo during the core study) with all procedures performed in accordance with the last planned visit of the safety follow-up (Visit 17), after which their participation in the study will be considered completed. Treatment period - all patients included in this period will receive open-label treatment with RPH-104 for 54 weeks. The possible drug dose will be: 80 mg once every 2 weeks subcutaneously; 160 mg once every 2 weeks subcutaneously. An injection of the study drug to patients is performed by qualified medical personnel every 2 weeks when the patient visits the study site; it is also possible for the patients to self-administer the drug at home (for which patients will be appropriately trained and provided with the necessary quantity of the drug, materials for the injection (including special containers for their disposal) and proper drug transportation). Safety and efficacy assessments are performed at Visit 1, Visit 2 (after 2 weeks) and then every 4 weeks according to the visits schedule. Safety and efficacy assessments are performed at Visit 1, Visit 2 (after 2 weeks) and then every 4 weeks according to the visits schedule.If FMF attack is confirmed in a patient, then patient's therapy can be adjusted based on the informed decision of an investigator: for patients who receive RPH-104 at a dose of 80 mg q2w, a dose can be increased to 160 mg q2w; for patients who already receive the maximum dose of RPH-104 that is 160 mg q2w, the dose will be not increased; these patients will be able to continue therapy with the study drug at a dose of 160 mg at the justified investigator's discretion. Reduction of the study drug dose is not planned in this study. Safety follow-up period - 8 weeks. After patients receive the last dose of the study drug at Week 54 of the study, the treatment period will be considered completed and an 8 weeks period of safety follow-up will start. During this period patients will have to visit the study site twice at Week 4 and Week 8 after the last dose of the study drug for safety assessments. Patients who have discontinued open-label therapy with the study drug early for any reason, should perform two safety follow-up visits at Week 4 and Week 8 after the last dose of the study drug.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Familial Mediterranean Fever, FMF
Keywords
RPH-104, colchicine inefficacy, colchicine intolerance, colchicine resistance, subcutaneous

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
60 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
RPH-104 80 mg q2w (160 mg q2w) depending on the dose in the core CL04018065 study
Arm Type
Experimental
Arm Description
RPH-104 80 mg once every 2 weeks subcutaneously or RPH-104 160 mg once every 2 weeks subcutaneously (In case of FMF attack development, patients who receive 80 mg of the drug may be switched to the increased maximum drug dose 160 mg based at the discretion of the investigator. A dose of 160 mg should be administered by two subcutaneous injections in two different quadrants.)
Intervention Type
Biological
Intervention Name(s)
RPH-104
Intervention Description
solution for subcutaneous administration 40 mg/mL, 2 mL in the 4-mL glass vial
Primary Outcome Measure Information:
Title
Incidence of Treatment-Emergent Adverse Events (AEs), by System Organ Class and Preferred Term
Time Frame
Up to 62 weeks
Title
Incidence of Treatment-Emergent Serious Adverse Events (SAEs), by System Organ Class and Preferred Term
Time Frame
Up to 62 weeks
Title
Incidence of Treatment-Emergent Adverse Events of Special Interest (AESI), by System Organ Class and Preferred Term
Time Frame
Up to 62 weeks
Title
Incidence rate for serious adverse events (SAEs)
Description
Incidence rate, expressed as the number of events per 100 patient-years of follow-up, for SAEs
Time Frame
Up to 62 weeks
Title
Incidence rate for adverse events of special Interest (AESI)
Description
Incidence rate, expressed as the number of events per 100 patient-years of follow-up, for AESI
Time Frame
Up to 62 weeks
Secondary Outcome Measure Information:
Title
Physician global assessment of disease activity scale (PGA)
Description
Percentage of patients with physician global assessment of disease activity scale (PGA) <2. PGA of disease activity involves a 5-point system: from 0 = no clinical signs and symptoms associated with the disease to 4 = severe clinical signs and symptoms associated with the disease.
Time Frame
Up to 62 weeks
Title
Percentage of patients with serological remission
Description
Percentage of patients with serological remission (i.e., C-reactive protein (CRP) level ≤10 mg/L).
Time Frame
Up to 62 weeks
Title
Percentage of patients whose Serum amyloid A (SAA) levels returned to normal values
Description
Percentage of patients whose SAA levels returned to normal values (i.e. SAA <10 mg/L)
Time Frame
Up to 62 weeks
Title
Percentage of patients who have experienced ≥ 1 attacks per month (since Day 0)
Description
Percentage of patients who have experienced ≥ 1 attacks per month (since Day 0). Criteria for the diagnosis of an attack are defined as the simultaneous development of clinical and serological signs of an attack, including: the score on the scale of global physician's assessment of disease activity (PGA) ≥ 2, suggesting "mild", "moderate" or "severe" activity of the disease (i.e., clinical signs), AND CRP level ≥ 30 mg/L (i.e. serological signs)
Time Frame
Up to 54 weeks
Title
Percentage of patients who have not had a single attack
Description
Percentage of patients who have not had a single attack. Criteria for the diagnosis of an attack are defined as the simultaneous development of clinical and serological signs of an attack, including: the score on the scale of global physician's assessment of disease activity (PGA) ≥ 2, suggesting "mild", "moderate" or "severe" activity of the disease (i.e., clinical signs), AND CRP level ≥ 30 mg/L (i.e. serological signs)
Time Frame
Up to 54 weeks
Title
Increase in the dose of the study drug
Description
Percentage of patients who required an increase in the dose of the study drug to 160 mg twice weekly.
Time Frame
Up to 54 weeks
Title
Additional symptomatic FMF therapy
Description
Percentage of patients who have received additional symptomatic FMF therapy with NSAIDs, paracetamol or glucocorticoids.
Time Frame
Up to 62 weeks
Title
Changes in the inflammatory markers over time
Description
Changes in the inflammatory markers over time - CRP
Time Frame
Up to 62 weeks
Title
Changes in the inflammatory markers over time
Description
Changes in the inflammatory markers over time - SAA.
Time Frame
Up to 62 weeks
Title
Changes in the PGA score over time
Description
Changes in the PGA score over time. PGA of disease activity involves a 5-point system: from 0 = no clinical signs and symptoms associated with the disease to 4 = severe clinical signs and symptoms associated with the disease.
Time Frame
Up to 54 weeks
Title
Changes in the severity of the main disease symptoms score
Description
Changes in the severity of the main disease symptoms score. An assessment of severity of the main symptoms of the disease will also be based on a 5-point scale for the following symptoms: chest pain, abdominal pain, arthralgia/arthritis, skin rash. The severity of each symptom should be evaluated as follows: 0 = no symptom, 1 = minimal, 2 = mild, 3 = moderate, 4 = severe.
Time Frame
Up to 54 weeks
Title
Changes in the renal function in patients with impaired renal function at the screening
Description
Changes in the renal function in patients with impaired renal function (ClCr <90 ml/min [calculated using the Cockcroft-Gault formula] at the screening)
Time Frame
Up to 62 weeks
Title
Changes in urinary protein levels in patients with proteinuria at the screening
Description
Median changes from baseline (timepoint week 0) to timepoint week 62.
Time Frame
Up to 62 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: The patient who completed the last visit of the treatment period in the core study, according to the protocol, during which he/she received at least one dose of RPH-104. Voluntarily signed and dated Patient Informed Consent Form for participation in this study. The patient's ability and desire, according to the investigator, to follow the schedule of visits, follow the study procedures and follow the protocol requirements, i.e they agree to: come to the study site every 2 weeks for the investigational product administration by qualified site staff. OR learn the subcutaneous injection technique and self-administer the investigational product at home as per protocol of this study. Exclusion Criteria: Any medically important event that was observed in a patient during his/her participation in the core study, and, in the opinion of the investigator, is a reason for not including this patient in the present study, and any other medical (including psychiatric) conditions or laboratory abnormalities, which may increase the potential risk associated with participation in the study and receiving the investigational product, or may affect the interpretation of the results of the study, and which, in the Investigator's reasonable opinion, result in the patient's non-compliance with the inclusion criteria Pregnant and/or lactating women or women planning pregnancy during the study or within 2 months after the last dose of the study drug. Women of childbearing potential, i.e. all women with the physiological ability to become pregnant (except for women with a final cessation of menstruation, which should be determined retrospectively after 12 months of natural amenorrhea, i.e. amenorrhea with an appropriate clinical status, for example, an appropriate age), who DO NOT agree to use highly effective contraception for of the entire study period, starting from the beginning of the screening phase (signing informed consent) and for a minimum of 8 weeks after the last dose of the study drug. OR Men who are sexually active and do NOT agree to use highly effective contraceptives throughout the study, starting from the beginning of the screening phase and for at least 8 weeks after the last dose of the study drug. Highly effective contraception methods include: sterilization in women: surgical bilateral removal of the ovaries (with or without removal of the uterus) or ligation of the fallopian tubes at least 6 weeks before the start of the study therapy. In the case of removal of only the ovaries, the reproductive status of a woman should be confirmed by a subsequent assessment of hormone level; sterilization in men, at least 6 months before the start of the study therapy with proper documentation of the absence of sperm in the ejaculate after vasectomy. For the women participating in the study, the sexual partner after a vasectomy should be the only partner; using a combination of any two of the following methods (a+b or a+c or b+c): the use of oral, injectable or implanted hormonal contraceptives; in the case of the use of oral contraceptives, women should constantly use the same drug for at least 3 months before the start of the study therapy; the installation of an intrauterine device or contraceptive system; barrier methods of contraception: condom or occlusive cap (diaphragm or cervical cap/contraceptive vaginal ring) with spermicidal foam/gel/film/cream/vaginal suppository. The need for systemic glucocorticoid therapy at doses > 0.2 mg/kg/day of prednisolone (0.16 mg/kg/day of methylprednisolone or an equivalent dose of another glucocorticoid) orally from the moment of signing the Informed Consent Form to the end of the period of therapy with the study drug. The need to use a live (attenuated) vaccine during the study or within 3 months after the last dose of the study drug. Live attenuated vaccines include vaccines against viruses: measles, rubella, mumps, chickenpox, rotavirus, flu (as a nasal spray), yellow fever, polio (oral polio vaccine); vaccines against tuberculosis (BCG), typhoid fever (oral typhoid vaccine) and typhus (typhus vaccine). Immunocompetent family members of the patient should not be vaccinated with the oral polio vaccine during the patient's participation in the study. Positive results of tuberculosis screening performed at Visit 10 of the core study (QuantiFERON-TB/T-SPOT.TB test, chest x-ray).
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Mikhail Samsonov
Organizational Affiliation
R-Pharm
Official's Role
Study Director
Facility Information:
Facility Name
Center of Medical Genetics and Primary Health Care LLC
City
Yerevan
ZIP/Postal Code
0001
Country
Armenia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Anna Egiazaryan
Phone
+ 374 10 544 367
Email
tamarasarkisyan@gmail.com
First Name & Middle Initial & Last Name & Degree
Anna Egiazaryan
Facility Name
Mikaelyan Institute of Surgery CJSC
City
Yerevan
ZIP/Postal Code
0052
Country
Armenia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Valentina Vardanyan
Phone
+374 99 066 115
Email
valentina.vardanyan@gmail.com
First Name & Middle Initial & Last Name & Degree
Valentina Vardanyan
Facility Name
LLC Tbilisi State Medical University and Ingorokva High Medical Technology University Clinic
City
Tbilisi
ZIP/Postal Code
0144
Country
Georgia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Tamta Kobakhidze
Phone
+ 995 568 404374
Email
Tamta.kobakhidze@yahoo.com
First Name & Middle Initial & Last Name & Degree
Tamta Kobakhidze
Facility Name
Inova LLC
City
Tbilisi
ZIP/Postal Code
0179
Country
Georgia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Nino Kiparoidze
Phone
+995 558 542 414
Email
nikimai@mail.ru
First Name & Middle Initial & Last Name & Degree
Nino Kiparoidze
Facility Name
Medical Technologies Ltd.
City
St.Petersburg
ZIP/Postal Code
191025
Country
Russian Federation
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Mikhail Kostik
Phone
+7 905 278 01 74
Email
kost-mikhail@yandex.ru
First Name & Middle Initial & Last Name & Degree
Mikhail Kostik

12. IPD Sharing Statement

Learn more about this trial

Safety and Efficacy of RPH-104 Used to Prevent Recurrent Fever Attacks in Adult Patients With Colchicine Resistant or Colchicine Intolerant Familial Mediterranean Fever

We'll reach out to this number within 24 hrs